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• Consensus recommendations for managing chronic suppurative 
lung disease (CSLD) and bronchiectasis, based on systematic 
reviews, were developed for Australian and New Zealand children 
and adults during a multidisciplinary workshop.
• The diagnosis of bronchiectasis requires a high-resolution 
computed tomography scan of the chest. People with symptoms of 
bronchiectasis, but non-diagnostic scans, have CSLD, which may 
progress to radiological bronchiectasis.
• CSLD/bronchiectasis is suspected when chronic wet cough persists 
beyond 8 weeks. Initial assessment requires specialist expertise. 
Specialist referral is also required for children who have either two 
or more episodes of chronic (>4 weeks) wet cough per year that 
respond to antibiotics, or chest radiographic abnormalities 
persisting for at least 6 weeks after appropriate therapy.
• Intensive treatment seeks to improve symptom control, reduce 
frequency of acute pulmonary exacerbations, preserve lung 
function, and maintain a good quality of life.
• Antibiotic selection for acute infective episodes is based on results 
of lower airway culture, local antibiotic susceptibility patterns, 
clinical severity and patient tolerance. Patients whose condition 
does not respond promptly or adequately to oral antibiotics are 
hospitalised for more intensive treatments, including intravenous 
antibiotics.
• Ongoing treatment requires regular and coordinated primary 
health care and specialist review, including monitoring for 
complications and comorbidities.
• Chest physiotherapy and regular exercise should be encouraged, 
nutrition optimised, environmental pollutants (including tobacco 
smoke) avoided, and vaccines administered according to national 
immunisation schedules.
• Individualised long-term use of oral or nebulised antibiotics, 
corticosteroids, bronchodilators and mucoactive agents may 
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provide a benefit, but are not recommended routinely.lth
dis
chA ough regarded in high-income countries as an orphanease,1,2 bronchiectasis remains a major contributor toronic respiratory morbidity in less-affluent populations,
both Indigenous3 and non-Indigenous.1,4,5 Moreover, delays in
diagnosis of bronchiectasis of years to decades commonly occur in
children4 and adults,6 and it is likely that many remain undiag-
nosed and untreated, risking premature and accelerated pulmon-
ary decline.7,8 This position statement from the Thoracic Society of
Australia and New Zealand (TSANZ ) and the Australian Lung
Foundation (ALF), developed at a multidisciplinary workshop,
presents consensus recommendations for managing chronic sup-
purative lung disease (CSLD), including bronchiectasis, in chil-
dren and adults in settings other than remote and rural Indigenous
Australian communities; recommendations for these communities
are available elsewhere.3 This statement provides an overview and
is not intended to replace individualised specialist care. As with all
guidelines, it does not substitute for sound clinical judgement,
particularly when addressing such a phenotypically heterogeneous
condition as bronchiectasis.9 The development process under-
taken by the working group is outlined in Box 1 and the full
position statement will be available on the TSANZ website (http://
www.thoracic.org.au/).
Objectives
1. To increase awareness of CSLD and bronchiectasis in chil-
dren and adults.
2. To encourage earlier diagnosis and improved management of
CSLD and bronchiectasis.
nsensus on
tasis.
sis and 
onchiectasis
are in children aged under 15 years. In New Zealand, the national
incidence of bronchiectasis is 3.7/100 000 per year,4 which is
almost twice that of cystic fibrosis, while in Central Australian
Indigenous children the estimated prevalence of bronchiectasis is
at least 1470/100 000.12 Estimated bronchiectasis prevalence rates
in the United States range from 4.2/100 000 in 18–34-year-olds to
272/100 000 in those over 75 years.13 Patients with bronchiectasis
were found to spend two more days in hospital and have higher
annual medical care expenditure (by US$5681) than age- and sex-
matched controls with other chronic illnesses, such as diabetes
and heart failure.13
Frequently used abbreviations
c-HRCT Chest high-resolution computed tomography
COPD Chronic obstructive pulmonary disease
CSLD Chronic suppurative lung disease
FEV1 Forced expiratory volume in 1 second
PsA Pseudomonas aeruginosa
QoL Quality of life
RCT Randomised controlled trial ◆ber 6 • 20 September 2010
POSITION STATEMENTBronchiectasis can be misdiagnosed as, or coexist with, other
chronic respiratory diseases. Between 29% and 50% of people
with chronic obstructive pulmonary disease (COPD) have bron-
chiectasis,3 as do as many as 40% of newly referred patients with
difficult-to-control asthma and a chronic cough;14 thus it is likely
that many people with chronic respiratory symptoms due to CSLD
or bronchiectasis remain undiagnosed.
Bronchiectasis causes premature death.15 The only published
Australian mortality data for bronchiectasis are from a hospital-
based cohort of 61 adults (mean [SD] age, 42 [15] years) in Central
Australia where 11.5% died within 12 months.15 In other countries,
mortality rates in adults with bronchiectasis vary widely, from 58%
survival at 4 years (Turkey) and 75% survival at 8.8 years (Finland)
to 81% survival at 14 years (Scotland).16 Complications and comor-
bidities associated with bronchiectasis extend beyond the respira-
tory system and include cardiac and psychological effects.17
Definitions and their limitations
The definitions of bronchiectasis, CSLD and protracted bacterial
bronchitis are compromised by overlapping symptoms and signs
that are not specific to an individual condition (Box 2). Thus, some
clinicians, particularly paediatricians, use the term CSLD for all
three conditions. Whether these three conditions are different, or
are part of a spectrum of disease severity, remains undetermined.18
While the principles of managing all three conditions are similar,
there are few published intervention studies, especially for man-
aging patients with CSLD. Consequently, many of the recommen-
dations for CSLD are extrapolated from studies of bronchiectasis.
Until further evidence is available, we believe including CSLD is
important given (i) the spectrum of disease; (ii) the increasing
evidence that early diagnosis and treatment improves outcomes
and reduces pulmonary decline;8,26,27 and (iii) the difficulties of
providing robust definitions.
Recommendation 1
1a. CSLD describes a clinical syndrome of respiratory symp-
toms and/or signs. Symptoms of chronic endobronchial suppu-
ration are a continuous, wet or productive cough for more than
8 weeks, with or without other features, such as exertional
dyspnoea, symptoms of reactive airway disease, recurrent chest
infections, growth failure, clubbing, hyperinflation or chest wall
deformity. In children, triggers for referral to a specialist
include: (i) two or more episodes of chronic (> 4 weeks) wet
cough per year responding to antibiotics; and (ii) a chest
radiograph abnormality persisting for more than 6 weeks after
appropriate therapy.
1b. Bronchiectasis refers to CSLD with the presence of radio-
logical features on a chest high-resolution computed tomogra-
phy (c-HRCT) scan.
Grade: strong; evidence: not applicable
Aetiology and investigations of a patient with CSLD/
bronchiectasis
Radiology
Plain chest radiographs are insensitive, and c-HRCT (conventional
or multidetector) scans, despite their limitations (Box 2), remain
the diagnostic gold standard. As children, adolescents and young
1 Development process of the position statement
GRADE approach to guideline development
The recommendations were based on the available evidence (Box 
5). Principles of evidence-based medicine and the revised GRADE10 
approach to guideline development were used to categorise 
recommendations into: strong, weak, or no specific 
recommendation.10
The implications of a strong recommendation are:10
• For patients — most people in your situation would want the 
recommended course of action and only a small proportion would 
not; request discussion if the intervention is not offered.
• For clinicians — most patients should receive the recommended 
course of action.
• For policymakers — the recommendation can be adopted as a 
policy in most situations.
The implications of a weak recommendation are:
• For patients — most people in your situation would want the 
recommended course of action, but many would not.
• For clinicians — you should recognise that different choices will be 
appropriate for different patients and that you must help each 
patient to arrive at a management decision consistent with her or 
his values and preferences.
• For policymakers — policy making will require substantial debate.
The levels of evidence provided by GRADE are:
High = Further research is very unlikely to change our confidence in 
the estimate of effect.
Moderate = Further research is likely to have an important impact on 
our confidence in the estimate of effect and may change the 
estimate.
Low = Further research is very likely to have an important impact on 
our confidence in the estimate of effect and is likely to change the 
estimate.
Very low = Any estimate of effect is very uncertain.
When relative risk was not available in publications, the decision to 
upgrade the evidence was based primarily on the likelihood of 
further research having an effect on the recommendation.
Database search
An updated search (from a previous search in October 20073) was 
conducted in July 2009 by one of us (A B C) using the text words 
“bronchiectasis” or “suppurative lung disease” and “controlled 
trials” in the PubMed and Cochrane Central Library databases. Only 
full articles published in English were retrieved. A draft of this 
document was circulated to all authors before a workshop held in 
Brisbane on 7 August 2009.
Consensus process
Recommendations were drafted and finalised by complete 
agreement by the eight authors who attended the workshop. The 
assigned evidence level (defined above) of recommendations was 
also obtained (complete agreement by the workshop attendees). 
This document and a summary table were then circulated to the 
entire group of 13 authors for assessment using the GRADE 
descriptors.10 Strength of recommendations were assigned by 
formal voting rules,11 and agreement with a statement by more than 
75% of the group was defined a priori as consensus. 
GRADE = Grading of Recommendations Assessment, Development and 
Evaluation ◆MJA • Volume 193 Number 6 • 20 September 2010 357
POSITION STATEMENTadults are at greater risk from radiation-induced cancers later in
life,24 the c-HRCT protocol must ensure the lowest possible
radiation exposure to obtain adequate assessment.28
Recommendation 2
Patients with symptoms and/or signs of CSLD require a c-
HRCT scan to confirm the diagnosis and to assess severity and
extent of bronchiectasis. Specialist advice is preferred before
ordering a c-HRCT scan for children.
Grade: strong; evidence: moderate
Aetiological associations
Several causative and associated factors are described for CSLD/
bronchiectasis (Box 3). Identifying aetiology and disease severity
can influence management, including treatment intensity.29,30
Investigations for specific causes of CSLD/bronchiectasis are rec-
ommended (Box 4), even though many patients will not have an
identifiable aetiology.3,4,9
Assessment of severity
In addition to routine clinical data (cough, sputum, exacerbation
rate, wellbeing, etc) and radiological assessment, objective tests
provide information about disease severity and prognosis.
Lung function
Bronchiectasis is primarily an airway disease and, although
spirometry data are classically obstructive, a restrictive pattern is
also recognised.5 Spirometry and lung-volume measurements
should be performed at diagnosis, and spirometry repeated at each
review, even though these tests can be relatively insensitive in mild
disease and in children.12 Many patients have a gradual deteriora-
tion in lung function over time.5,7 If serial pulmonary function
tests indicate disease progression, a step-up in therapy is usually
required. Studies in children show that spirometric volumes can
stabilise and even improve.8,26,27 In adults with moderate-to-
severe bronchiectasis, mortality risk is associated with the degree
of lung-function impairment.16 Other tests, including complex
pulmonary-function tests and the 6-minute walk test, are some-
times used for determining functional impairment, but these are
not discussed further.
Microbiology
Surveillance of airway or sputum microbiology helps guide anti-
biotic therapy in CSLD/bronchiectasis,31 especially if there is
deterioration or inadequate response to current treatment. The
most common pathogens recovered from children are non-typea-
ble Haemophilus influenzae, Streptococcus pneumoniae and Moraxella
catarrhalis.4,32 In adults, Pseudomonas aeruginosa and non-typeable
H. influenzae predominate.33 About 25%–45% of airway samples
fail to grow pathogenic bacteria. As disease progresses, the micro-
biological flora changes, often with P. aeruginosa appearing in more
advanced disease and predicting a worse prognosis.33 Aspergillus
and non-tuberculous mycobacteria species are detected in some
adults with bronchiectasis, although their pathogenic role is often
uncertain.33 Nonetheless, non-tuberculous mycobacteria have
been implicated in exacerbations31 and pulmonary deterioration.34
2 Definitions
Bronchiectasis
Bronchiectasis is a radiological or pathological diagnosis characterised by 
abnormal irreversible bronchial dilatation. It is mostly diagnosed by a chest 
high-resolution computed tomography (c-HRCT) scan, which is the current 
diagnostic gold standard. However, a radiological diagnosis of 
bronchiectasis may be reported by radiologists in patients with interstitial 
lung diseases (eg, pulmonary fibrosis) where traction on the airways causes 
bronchial dilatation. Traction bronchiectasis in the absence of a chronic 
productive cough will not be considered further in this position statement.
In adults, the dominant presenting symptom is a chronic or recurrent 
productive cough. In children, the cough is wet rather than productive, 
as young children do not usually expectorate,18 and after treatment the 
cough often temporarily resolves.19
Chronic suppurative lung disease (CSLD)
CSLD describes a clinical syndrome in which there are symptoms 
indicating chronic endobronchial suppuration (see Recommendation 
1a, page 357) with or without evidence of radiological bronchiectasis on 
c-HRCT scans. However, absence of symptoms (other than wet cough) 
and signs does not reliably exclude either bronchiectasis or CSLD. Lung 
abscess and empyema (previously considered as within the CSLD 
spectrum) have distinct radiological characteristics and are not 
discussed here.
Chronic infective bronchitis and protracted bacterial bronchitis
Most patients have a productive or wet cough for several years before a 
diagnosis is made.5,12 Pathobiological studies and clinical observations 
suggest many patients have bronchitis initially that, if left untreated, 
gradually evolves into bronchiectasis.18 The entity of protracted bacterial 
bronchitis has been used in relation to children in whom a prolonged wet 
cough completely resolves after antibiotic treatment.18 Many of these 
children were previously misdiagnosed with asthma and had responded 
poorly to asthma therapies. In some settings these children would have 
been classified as having “difficult or severe asthma”.18,20 We also suspect 
that a proportion of adults diagnosed with “difficult” and/or neutrophilic 
asthma in fact have bronchiectasis as their primary diagnosis. In a recent 
study, 40% of newly referred adults with “difficult asthma” were found to 
have bronchiectasis.14 While the evidence is limited, it is highly likely that, 
in some circumstances, untreated bronchitis progresses to bronchiectasis 
and/or airflow limitation.18 The definitions of bronchiectasis, CSLD and 
protracted bacterial bronchitis have limitations, as their associated 
symptoms and signs overlap and lack specificity. However, absolute 
reliance on a radiology-based definition is also unsatisfactory for the 
following reasons:
1. It is not known when diagnostic radiological changes of bronchiectasis 
appear in the course of the illness in patients with symptoms of CSLD/
bronchiectasis. Studies in adults found that bronchography (the old 
diagnostic gold standard) is superior to a c-HRCT scan at detecting 
bronchiectasis, especially when mild disease is present.21 Another study 
reported that by using a 16-slice computed tomography scan of the chest 
(contiguous 1-mm slices), 40 extra lobes with evidence of bronchiectasis 
were identified in 53 adults previously examined by conventional c-HRCT 
scans.22
2. One of the key signs of bronchiectasis on c-HRCT scans, increased 
bronchoarterial ratio, is significantly influenced by age.23 However, it 
remains to be determined whether a lower bronchoarterial ratio should 
be used in children.
3. At least two c-HRCT scans are required to fulfil the criteria of “irreversible 
dilatation”. Nonetheless, performing more than one c-HRCT scan purely 
for diagnostic, as opposed to management, reasons is controversial 
because of the small, but increased, radiation-induced cancer risk24 and, 
moreover, is often impractical in some settings.
4. c-HRCT scans performed during various clinical states, such as during 
an acute respiratory illness, immediately after treatment and when 
clinically stable, can yield different results.3,25 ◆358 MJA • Volume 193 Number 6 • 20 September 2010
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Pulmonary arterial hypertension complicates severe CSLD/bron-
chiectasis.12 In advanced disease, chronic or nocturnal hypox-
aemia is common, and selected patients require arterial blood gas,
an echocardiogram and an overnight oxygen assessment.
Recommendation 3
When CSLD/bronchiectasis is present, obtaining further infor-
mation about specific underlying causes may determine subse-
quent investigation and management. History taking should
include questions on:
• parameters suggestive of cystic fibrosis (family history, pan-
creatitis, chronic gastrointestinal symptoms, male infertility);
and
• underlying immune deficiency (male infertility, recurrent
sinusitis, extrapulmonary infections including discharging
ears and severe dermatitis).
Grade: strong; evidence: moderate
Recommendation 4
When CSLD/bronchiectasis is present, perform or refer for
baseline investigations (Box 4).
Grade: strong; evidence: moderate
Management (Box 5)
Early and effective management reduces short- and long-term mor-
bidity.8,26,27,40 In primary ciliary dyskinesia, adults diagnosed late
have significantly poorer lung function.41 With appropriate treat-
ment, lung disease complicating primary immunodeficiency should
not deteriorate.8,27 In a Melbourne cohort, longer duration of chronic
productive cough was related to reduced lung function.9 At the initial
referral, the mean percentage predicted, forced expiratory volume in
1 second (FEV1) in those in the cohort with chronic cough from
childhood was 18% lower than those with adult-onset symptoms.9
Recommendation 5
Aim to optimise general wellbeing, symptom control, lung
function and quality of life (QoL); and to reduce exacerbation
frequency and prevent excessive decline in lung function. This
may require intensive medical therapy.
Grade: strong; evidence: high
Antibiotics
CSLD/bronchiectasis arises from infection and an ineffective host
immune response involving uncontrolled recruitment and activation
of inflammatory cells within the lower airways.42 The subsequent
release of mediators, such as proteases and free radicals, causes
bronchial-wall injury and dilatation.42 Consequently, intensive anti-
biotic treatments are advocated to reduce the microbial load. For
acute exacerbations, depending on the severity of the episode, oral
antibiotics and ambulatory care are usually tried first.19 More severe
exacerbations require hospitalisation with intravenous antibiotics
combined with intensified physiotherapy and other airway clearance
methods, including nebulised therapy.19,40
Response to therapy includes reduction in sputum volume and
purulence, improvement in cough characteristics (wet to dry or
cessation of cough), general wellbeing, QoL and markers of
systemic inflammation (C-reactive protein), demonstration of
microbial clearance, and “return to baseline” state.19,40
Prolonged oral or inhaled antibiotic treatments are sometimes
used to improve QoL and to prevent exacerbations, although the
evidence is limited and the possibility of developing antibiotic
resistance is of concern. There is increasing interest in macrolides
for this purpose; however, further studies are required to establish
their role in CSLD/bronchiectasis. Additionally, before using mac-
rolides long-term, the presence of non-tuberculous mycobacteria
4 Minimum investigations for bronchiectasis
The minimum investigations are:
• A full blood count and tests for levels of the major 
immunoglobulin classes IgG, IgA, IgM, and IgG subclasses
• A sweat test
• Culture of airway secretions, including specialised cultures for 
mycobacteria, particularly non-tuberculous mycobacteria, in 
sputum-producing patients
• Spirometry and lung volumes (when aged > 6 years)
• Serological tests for Aspergillus, and total IgE level in adults
• Test for primary ciliary dyskinesia in children (if expertise available) — 
exhaled fractional nasal nitric oxide and/or nasal ciliary brushings
In addition, consider the following:
• Test for cystic fibrosis transmembrane conductance regulator 
(CFTR) gene mutations
• Bronchoscopy for foreign body or airway abnormality, and to 
obtain specimens for culture of respiratory pathogens, including 
mycobacteria
• Barium swallow
• Additional immunological tests — total IgE level in children; 
neutrophil function tests and lymphocyte subsets; and antibody 
responses to protein and polysaccharide antigens (eg, tetanus 
toxoid and pneumococcal vaccination)
• Test for primary ciliary dyskinesia (in adults when expertise for this 
is available) — exhaled fractional nasal nitric oxide and/or nasal 
ciliary brushings
• Test for HIV
• Echocardiogram, especially in adults (when concerned about 
pulmonary hypertension) ◆
3 Aetiologies and factors associated with bronchiectasis
• Congenital causes (eg, Mounier-Kuhn syndrome, Young’s 
syndrome)
• Chronic obstructive pulmonary disease and smoking
• Cystic fibrosis
• Mucociliary dysfunction (eg, primary ciliary dyskinesia)
• Primary or secondary immune deficiency (eg, 
hypogammaglobulinaemia, lung and bone-marrow 
transplantation, malignancy, HIV/AIDS)
• Pulmonary fibrosis and pneumoconiosis (eg, silicosis)
• Post-obstruction (eg, with a foreign body)
• Post-infection (eg, tuberculosis, adenovirus, recurrent pneumonia)
• Recurrent small-volume aspiration (eg, from upper airway 
secretions or gastric contents)
• Systemic inflammatory diseases (eg, rheumatoid arthritis, 
sarcoidosis) ◆MJA • Volume 193 Number 6 • 20 September 2010 359
360 MJA • Volume 193 Number 6 • 20 September 2010
POSITION STATEMENT
5 Possible interventions and the evidence base for management of chronic suppurative lung disease and bronchiectasis
Evidence type/study Summary of results Notes
Antibiotics (by type) 
General Cochrane review, other 
systematic review*
Generally beneficial. See section on Antibiotics 
(page 359) 
Antibiotic resistance
Macrolides RCTs and review for 
2–6 months*
Exacerbations significantly reduced in 
treatment arm; sputum volume and symptoms 
reduced; some patients showed 
improvement in pulmonary function tests*
Concerns over antibiotic resistance
Nebulised tobramycin Double-blind crossover 
RCT in 30 patients with PsA,
6 months in each arm*
Fewer admissions and days in hospital in 
tobramycin arm
Antibiotic resistance; nebulised 
tobramycin poorly tolerated by some 
patients* 
Antibiotics (by duration) 
Short term (< 1 month) Several cohort studies* General clinical improvement 
Medium term (1–11 
months)
Cochrane review, other 
systematic reviews*
Improvement with amoxycillin and macrolides 
(see above). Adults with PsA had shorter 
hospitalisations, but no change in QoL*
Long term ( 12 months) RCTs* Adults with PsA had fewer admissions and days in 
hospital.* Reduced general disability in those 
taking tetracycline compared with placebo*
Anti-inflammatories
Oral NSAIDs Cochrane review* No RCTs Cohort study of indomethacin (25 mg 
three times a day for 28 days) 
reduced neutrophil chemotaxis, but 
no change in sputum albumin, 
elastase or myeloperoxidase levels*
Inhaled indomethacin Cochrane review35 RCT in 25 adults, some with CSLD. Reduced 
sputum volume and improved dyspnoea score
Mucolytics
Bromhexine Cochrane review* Studies only in acute phase Not universally available
Recombinant human 
deoxyribonuclease
Systematic review* Increased exacerbation rate and accelerated 
decline in FEV1 
Airway clearance
Chest physiotherapy Cochrane review* and 
RCTs36,37
Two small trials in patients with bronchiectasis. 
Recent RCT37 showed benefit for cough and 
subjective scores, exercise capacity and 24-hour 
sputum volume. A study in children showed 
improvement in sputum volume and FEV1
36
Inhaled hyperosmolar 
agents
Cochrane review, additional 
RCT (non-blinded) using 
7% hypertonic saline*
Two small short-term studies of mannitol 
showed benefit in QoL only
Asthma therapies
Inhaled corticosteroids Cochrane review38 No difference in any outcome when only 
RCTs of inhaled corticosteroids v placebo 
were included. Reduced exacerbation rate 
in adults with PsA
Limited applicability in children, as 
high doses are used and children are 
less likely to have PsA
Oral corticosteroids Cochrane review* No RCTs No data*
Anticholinergics Cochrane review* No RCTs No data*
β2 Agonist Cochrane review* No RCTs No data*
Leukotriene receptor 
antagonist
Cochrane review* No RCTs No data*
CSLD = chronic suppurative lung disease. FEV1 = forced expiratory volume in 1 second. NSAIDs = non-steroidal anti-inflammatory drugs. PsA = Pseudomonas 
aeruginosa. QoL = quality of life. RCT = randomised controlled trial.
* No other data found by single-reviewer PubMed search — July 2009 (for references, see Chang AB, Grimwood K, Macguire G, et al3; and Chang AB, Redding GJ, 
Everard ML18). ◆
POSITION STATEMENTshould be excluded in adults and in older children capable of
providing sputum samples.43
Recommendation 6
Antibiotic selection (Box 6) is based on lower airway culture
results (sputum or bronchoscopy washings) when available,
local antibiotic susceptibility patterns, clinical severity and
patient tolerance, including allergy.
Grade: strong; evidence: moderate
Recommendation 7
In patients not requiring hospitalisation for an acute exacerba-
tion of CSLD/bronchiectasis, oral antibiotics are prescribed for
at least 10 days. Close follow-up to assess treatment effect is
necessary.
Grade: strong; evidence: low
Recommendation 8
An inadequate response to antibiotic treatment should prompt
repeat of lower airway cultures and assessment of whether
hospital admission is needed.
Grade: strong; evidence: moderate
Recommendation 9
Patients with an acute exacerbation of CSLD/bronchiectasis
which does not respond to oral antibiotic therapy should
receive supervised hospital-based therapy, including intensive
airway clearance strategies, and intravenous antibiotics deter-
mined by the latest lower-airway culture results. In most cases,
this requires hospitalisation for at least 7 days.
Grade: strong; evidence: moderate
Recommendation 10
Long-term oral antibiotics, including macrolides, should not be
prescribed routinely. They may, however, be considered for a
trial in selected patients (eg, those with frequent respiratory
exacerbations [more than six exacerbations and/or more than
two hospitalisations over 12 months] or more than 6 months of
continuous symptoms; the frequency and time frames are
arbitrary and based on expert opinion). Before commencing
macrolides, non-tuberculous mycobacterial infection should be
excluded in all patients capable of providing a sputum speci-
men.
Grade: strong; evidence: moderate
5 Possible interventions and the evidence base for management of chronic suppurative lung disease and bronchiectasis 
(continued from previous page)
Evidence type/study Summary of results Notes
Physical training
Cochrane review and RCT, 
which was included in 
Cochrane review as an 
abstract (data changed)*
Pulmonary rehabilitation improves exercise 
tolerance, no additional advantage of 
simultaneous inspiratory muscle training
Oxygen (domiciliary)
No data as sole therapy* Consider data from patients with COPD 
showing benefit in survival*
Surgery
Cochrane review* No RCTs. Cohort studies suggest a benefit 
in selected cases* 
Reduction in exacerbation rate 
similar in medically treated group.* 
Adverse events of surgery*
Vaccines
Pneumococcal conjugate 
and polysaccharide 
vaccines
Cochrane review39 Single RCT in adults that was inclusive of 
COPD and other chronic lung disease 
Advocated, as vaccines reduce 
pneumococcal infection risk and 
respiratory infections
Influenza vaccines Cochrane review* No RCTs Advocated in accordance with 
national guidelines
Acupuncture
RCT* Improvement in QoL but no effect on sputum 
volume or the 6-min walk test
Model of follow-up 
Nurse led Cochrane review* No difference in exacerbations, but increase 
in hospitalisations in nurse-led care compared 
with doctor-led care
Increased health care cost 
implications
COPD = chronic obstructive pulmonary disease. QoL = quality of life. RCT = randomised controlled trial.
* No other data found by single reviewer search on PubMed (July 2009) (for references, see Chang AB, Grimwood K, Macguire G, et al3; and Chang AB, 
Redding GJ, Everard ML18). ◆MJA • Volume 193 Number 6 • 20 September 2010 361
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Nebulised antibiotics, such as gentamicin, tobramycin and
colistin, should not be prescribed routinely. However, a thera-
peutic trial in selected patients with frequent exacerbations (as
per Recommendation 10) may be considered.
Grade: strong; evidence: moderate
Bronchodilators and corticosteroids
Patients with CSLD/bronchiectasis may have coexistent asthma
with wheeze and/or dyspnoea that is responsive to β2-agonist
medications. Reports on asthma symptoms in those with CSLD/
bronchiectasis vary from 11% to 46%.2,44 While, in some studies,
bronchiectasis is ascribed to asthma, it is more likely in such cases
that asthma was initially misdiagnosed or coexisted with CSLD/
bronchiectasis.18,20 When present, asthma therapies should be
used in accordance with asthma guidelines.
Inhaled corticosteroids provide, at best, a modest benefit in
CSLD/bronchiectasis, including in patients with P. aeruginosa
infection.38 A Cochrane review found no significant differences
between patients receiving very high inhaled corticosteroid doses
(2 g/day) and placebo controls.38
Recommendation 12
Inhaled and oral corticosteroids should not be routinely pre-
scribed unless there is an established diagnosis of coexisting
asthma.
Grade: strong; evidence: low for oral corticosteroids, moder-
ate for inhaled corticosteroids
Recommendation 13
Inhaled bronchodilators should not be routinely prescribed and
should be used only on an individual basis.
Grade: strong; evidence: low
Mucolytics and mucoactive agents
Mucoactive agents include mannitol and hypertonic saline. Ran-
domised controlled trials (RCTs) of these agents are in progress
with promising efficacy. While there is currently insufficient
evidence to justify their use, our recommendation to avoid these
mucolytics may change. In contrast, recombinant human deoxyri-
bonuclease (rhDNase), a widely used mucolytic in cystic fibrosis,
is harmful in adults with CSLD/bronchiectasis, as it is associated
with increased exacerbations and hospitalisations, and more rapid
decline in FEV1.
45
Recommendation 14
Recombinant human deoxyribonuclease is contraindicated in
CSLD/bronchiectasis.
Grade: strong; evidence: high
Recommendation 15
Mucoactive agents, including hypertonic saline and mannitol,
are currently not recommended.
Grade: weak; evidence: low
Chest physiotherapy, airway clearance methods, exercise 
and pulmonary rehabilitation
Despite lacking a robust evidence base, chest physiotherapy to
improve airway secretion clearance is standard treatment in
children36 and adults37,46 with CSLD/bronchiectasis. Nevertheless,
available studies suggest chest physiotherapy is beneficial, with
improved QoL and exercise capacity and reduced cough and
sputum volumes.37,46 Given the various techniques in airway
clearance and the increased efficacy when therapy is individual-
ised,36 specific chest physiotherapy expertise should be sought.
Pulmonary rehabilitation is employed in several different
chronic respiratory conditions. It involves a multidisciplinary
approach, including exercise training, self-management education,
6 Empirical antibiotic therapy and treatment for specific pathogens — chronic suppurative lung disease and bronchiectasis
Mild-to-moderate exacerbation (oral therapy) Severe exacerbation (intravenous therapy) 
Initial empirical therapy* Amoxycillin–clavulanate or doxycycline† Children: cefuroxime,‡ cefotaxime or ceftriaxone.
Adults: ticarcillin–clavulanate or ceftazidime ± tobramycin§
Haemophilus influenzae 
-Lactamase negative Amoxycillin Ampicillin
-Lactamase positive Amoxycillin–clavulanate or doxycycline† Cefuroxime,‡ cefotaxime or ceftriaxone
Streptococcus pneumoniae Amoxycillin Benzylpenicillin G 
Moraxella catarrhalis Amoxycillin–clavulanate Cefuroxime,‡ cefotaxime or ceftriaxone 
Staphylococcus aureus Dicloxacillin/flucloxacillin Flucloxacillin
Methicillin-resistant 
Staphylococcus aureus
Seek specialist advice Seek specialist advice
Pseudomonas aeruginosa Ciprofloxacin (maximum of 14 days) Children and adults: ticarcillin–clavulanate or 
ceftazidime ± tobramycin§
Non-tuberculous mycobacteria Seek specialist advice Seek specialist advice 
* In addition to clinical severity, initial empirical therapy is also guided by any previous lower-airway culture results (sputum or bronchoscopy washings), local antibiotic 
susceptibility patterns and prior responses to antibiotic treatments. In children too young to expectorate sputum and when no previous lower-airway culture results are 
available, prescribed empirical antibiotic therapy should be active against H. influenzae, S. pneumoniae and M. catarrhalis, the respiratory bacterial pathogens most 
commonly found in this age group. † Doxycycline is used only in adults and children over 8 years of age. ‡ Available in New Zealand. § Emerging evidence in adults (but 
not children) indicates that treating P. aeruginosa infection with combined β-lactam and aminoglycoside antibiotic therapy provides no additional clinical benefit and is 
associated with more frequent adverse events than treatment with a single β-lactam agent. ◆362 MJA • Volume 193 Number 6 • 20 September 2010
POSITION STATEMENTand psychosocial and nutritional intervention.47 Inspiratory mus-
cle training may be beneficial in adults with bronchiectasis. A
recent small RCT showed that an 8-week program of pulmonary
rehabilitation and inspiratory muscle training significantly
improved the incremental shuttle walking test.48 Unless specific
contraindications exist, physical activity should be encouraged.
Recommendation 16
Airway clearance manoeuvres are recommended and a chest
physiotherapist’s advice should be sought. Chest physiotherapy
should be individualised.
Grade: strong; evidence: moderate
Recommendation 17
Adults with CSLD/bronchiectasis and moderately severe, lim-
ited exercise tolerance and/or evidence of physical decondition-
ing should receive pulmonary rehabilitation.
Grade: strong; evidence: moderate
Recommendation 18
Regular physical activity is recommended for children and
adults with CSLD/bronchiectasis.
Grade: strong; evidence: high
Nutrition
Poor nutrition (both macro- and micronutrition) compromises
innate and adaptive immunity. Studies in other chronic respiratory
diseases49 indicate that poor nutrition may be a risk factor for
respiratory exacerbations in CSLD/bronchiectasis.
Recommendation 19
Assess and optimise nutritional status.
Grade: strong; evidence: moderate
Minimisation of further lung injury
Environmental pollutants, including tobacco smoke, exacerbate
chronic respiratory disorders and constitute an additional risk
factor for those with CSLD/bronchiectasis.
Recommendation 20
Promote elimination of smoking, including second-hand
smoke exposure.
Grade: strong; evidence: high
Assessment for comorbidities
Patients with CSLD/bronchiectasis have increased rates of comor-
biditiy, including chronic sinusitis, gastro-oesophageal reflux and
“asthma-like” disease. It is unknown whether such comorbidities
increase the frequency and/or severity of exacerbations or worsen
lung injury.
Recommendation 21
Regularly monitor and manage complications and comorbidi-
ties (Box 7). When present, these are managed according to
standard guidelines.
Grade: strong; evidence: moderate
Other treatments
Various other treatments are available, but with little supportive
data (Box 5). Current management strategies have reduced the
need for surgical interventions, which carry a small but significant
risk of morbidity and mortality. Lung transplantation should be
considered in those with end-stage lung disease.
Recommendation 22
Surgery is not normally indicated. There may be some circum-
stances that require assessment by a multidisciplinary team
expert in CSLD/bronchiectasis care.
Grade: strong; evidence: moderate
Public health issues, prevention and appropriate health 
care delivery
The socioeconomic determinants of health, including their impact
on prevalence and disease progression of CSLD/bronchiectasis,
cannot be adequately addressed here. Immunisations that prevent
acute respiratory infections are recommended despite the lack of
specific evidence in relation to bronchiectasis. For pneumococcal
immunisation, limited evidence supports using the 23-valent
pneumococcal polysaccharide vaccine for reducing acute infective
exacerbations.39
Delivery of chronic disease programs requires comprehensive
and highly skilled primary health care services. Education of
primary health care providers should focus on identifying children
and adults for appropriate referral and high-quality local manage-
ment. Initial assessment requires specialist expertise. Like other
chronic illnesses, individualised and multidisciplinary case man-
agement operating within an interprofessional framework is opti-
mal.50 Similarly, clinical deterioration should prompt early referral
for specialist care. Those with moderate or severe disease are best
managed by a multidisciplinary approach to chronic care.
Recommendation 23
All children should have routine vaccinations according to
national immunisation schedules. Ensure timely annual influ-
enza vaccination and that pneumococcal vaccines are adminis-
tered according to national guidelines.
Grade: strong; evidence: moderate
7 Reviewing patients with chronic suppurative lung 
disease or bronchiectasis
Review should be undertaken at least annually in adults and 
6-monthly in children. Involvement of a multidisciplinary team is 
preferable, especially at the initial evaluation. The review includes 
assessment of:
• severity, which includes oximetry and spirometry
• sputum culture
• management of possible complications and comorbidities, 
particularly for gastro-oesophageal reflux disease, reactive 
airway disease/asthma, chronic obstructive pulmonary disease, 
otorhinolaryngeal disorders and dental disease
• Less commonly, patients require assessment for sleep 
disordered breathing, cardiac complications, and referral for 
lung transplantation ◆MJA • Volume 193 Number 6 • 20 September 2010 363
POSITION STATEMENTRecommendation 24
Coordination of care among health care providers is neces-
sary. If bronchiectasis is suspected, specialist evaluation is
recommended to confirm diagnosis, investigate aetiology,
assess baseline severity and develop management plans.
Those with moderate or severe disease are best managed by
a multidisciplinary approach to chronic care, with individu-
alised case management. Clinical deterioration should
prompt early referral to services with CSLD/bronchiectasis
expertise.
Grade: strong; evidence: high
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